MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$3.86 USD
+0.07 (1.85%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $3.96 +0.10 (2.59%) 7:50 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
MARKER THERAPEUTICS, INC. [MRKR]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Phase II AML Trial Timeline May Shift. Reduce PT to $8 And Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Q219 - Pancreatic Cancer and AML Remain on Focus for the Rest of 2019
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Multi-Antigen Cell Therapy In Solid Tumors Just Might Work
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Marking The Pancreatic Cancer Data
Provider: Roth Capital Partners, Inc.
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Cell Therapy 2.0: Moving Beyond CAR-Ts in Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a $10 PT
Provider: Roth Capital Partners, Inc.